drugset
drugset / Trial / NCT06006598

A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men

NCT06006598 ↗

Phase 1 Completed 50 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 1584862 in healthy male subjects following administration of multiple rising doses.

Timeline

Start
2023-08-28
Primary completion
2024-05-05
Completion
2024-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1584862 Unknown — Oral
Background Midazolam Small molecule — —

Indications

No indication recorded.